PERISCOPE and the effect of pioglitazone on the progression of coronary artery disease in patients with diabetes

Abstract

References

1. Dormandy JA Charbonnel B , Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 2005;366:1279–89.

2. Haffner SM Greenberg AS , Weston WM , Chen H , Williams K , Freed IM. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679–84.

3. Marx N Froehlich J , Siam L et al. The antidiabetic PPARg-activator rosiglitazone reduces MMP-9 serum levels in type-2 diabetic patients with coronary artery disease. Arterioscl Thromb Vasc Biol 2003;23:283–8.

4. Mazzone T Meyer PM , Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572–81.

5. Sidhu JS Cowan D , Kaski CJ. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003;42:1757–63.

6. Sidhu JS Kaposzta Z , Markus HS , Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004;24:930–4.

7. Nissen SE Nicholls SJ , Wolski K et al. Comparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561–73.